1 Jennifer Kuzma USDA Rule Panel, 6-5-2020

•Download as PPTX, PDF•

0 likes•50 views

Perspectives on the new USDA regulations for GM Crops | GES Colloquium, Part 1 - USDA Oversight Past to Present Video at https://go.ncsu.edu/ges-mediasite Chat resources at https://go.ncsu.edu/ges-usda-panel-chat-links

Presentations & Public Speaking

USDA Oversight Past to Present
JENNIFER KUZMA, PHD
CO-DIRECTOR OF GES CENTER
GOODNIGHT-NC GSK FOUNDATION DISTINGUISHED PROFESSOR
SCHOOL OF PUBLIC AND INTERNATIONAL AFFAIRS
Disclaimer:
We are academics trying to understand the new rule. Although we have decades of
experience working with GM crop regulation and genetic engineering & societal issues,
we do not claim to have all the answers about the details or impacts on different sectors.
We are presenting how we understand the process and issues for discussion purposes.
Thank you!

Coordinated Framework for Regulation of Biotechnology
No new categories of risks, no new laws needed, “product not process”
EPA BiopesticideFDA GM plant food/feed—FFDCA
• Voluntary
• No determination of safety
USDA Plant Pest Act
• GM plants with plant pest DNA
sequences
EPA FIFRA
• plant incorporated protectants (Bt)
All other plants have been exempted since
mid 2000s-2010
• USDA Am I Regulated Process

2017
Proposed
Rule
Invokes
Noxious
Weed and
Plant Pest
Authorities
2020
SECURE
Rule
Only Plant
Pest Risk
Authorities
2008
Proposed
Rule
Invokes
Noxious
Weed and
Plant Pest
Authorities
Bush II
to Obama
Obama
to Trump
Gene editing arises

Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) rule
“organisms modified through GE”
GE is “techniques that use recombinant, synthesized, or amplified nucleic acids to modify or createa genome”
Organism that can directly or indirectly injure, cause damage to, or cause disease in any plant or plant product

Pros and Cons of SECURE
PROS
Shift to Plant Pest Risk Focus and away from
DNA presence
Tiered approach—exempt things with which
we have experience
Provisioning of information and FR comment
period for some categories
 E.g new USDA exemptions for what could be
achieved from conventional breeding
CONs
•Failure to invoke Noxious Weed provisions of
PPA---despite main risks of 1st gen GM crops
•Exemptions having little to do with potential
product risk
•Lack of public information for self or USDA
confirmed exempt
•Lack of formal assessment & comment period
in FR for RSR determinations

Estimate of $8.3M annual cost
savings to private industry
$3.4 M cost to APHIS
Not over $100M so no CBA
mandated by EO 12866
USDA Timeline of
Implementation
of SECURE

This document summarizes the US Food and Drug Administration's (FDA) regulatory approach and activities related to agricultural biotechnology products. It discusses the FDA's 1992 policy on genetically engineered plant-derived foods, which states that foods will be regulated based on their characteristics rather than the method used to develop them. The document also summarizes the FDA's guidance and requests for comment on the regulation of genome edited plants and animals. It outlines the FDA's commitment to facilitating innovation while ensuring safety and maintaining public confidence.

Dr. Patrick Webb - Emerging Disease Response Planning

John Blue

Ferrofluid in Medicine: Action Proposal

Eric Lamal

Within the next 5-7 years, ferrofluids will be safely used to treat and cure diseases like cancer through contributions from NASA, Ferrotec, the FDA, and CDRH, which will allow minimal side effects from cancer treatment and potentially turn cancer into a non-deadly disease within 20 years, though risks like patient allergies and misdirecting the fluid need mitigation through allergy tests and operator training.

Leading Molecules to Market - An overview on licensing

BananaIP Counsels

Company Profile

Inovio Pharmaceuticals, Inc.

The document summarizes recent advances at Inovio Pharmaceuticals, including being selected as a top translational researcher, generating immune responses in head and neck cancer patients, and protecting animals from Zika infection. It then discusses Inovio's plans to initiate a phase III trial for its HPV immunotherapy in 1H17 after an FDA request for additional information, and its partnership with MedImmune to develop immuno-oncology combination therapies. The document provides an overview of Inovio's immunotherapy technology platform and its potential applications in infectious diseases and cancer.

Regulatory aspects associated to genome editing in India

OECD Environment

This document summarizes India's existing biosafety regulatory framework for genetically modified organisms (GMOs) and gene technologies. It provides an overview of the key agencies and committees that regulate GMOs in India according to the Rules for Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/GMOs. It also outlines the process for approving GM crops in India and notes that new gene technologies will be regulated under the existing framework while appropriate guidelines are developed. Currently, GM cotton, brinjal, and mustard have been commercialized or are awaiting approval in India.

Early and accurate detection of bacterial pathogens

Plant Biosecurity Cooperative Research Centre

This document summarizes a research project that aims to develop accurate and rapid diagnostic tools for detecting exotic bacterial plant pathogens through genome-informed design. The project is developing PCR and LAMP-based diagnostics for key pathogens like Erwinia amylovora and Xanthomonas citri. Field-deployable tools like LAMP and RPA are also being validated for "smart surveillance" directly in the field. The diagnostics and training provided by this research will benefit biosecurity agencies, diagnostic laboratories, and the horticultural industry by facilitating early detection and a rapid response to incursions.

Regulatory aspects associated to genome editing in Australia - situation for...

OECD Environment

This document summarizes a research project studying the molecular response of tephritid fruit flies to sublethal stresses. The project aims to: 1) Identify the molecular pathways activated in fruit flies exposed to heat, cold, radiation, and parasitic infection stresses. 2) Construct a regulatory network of stress response genes in two key fruit fly pests. 3) Validate specific genes' roles in stress response through functional assays. The goal is to develop more effective and environmentally friendly postharvest treatments for controlling fruit flies, providing benefits to the horticulture industry, government pest management strategies, and researchers.

Quarantine and surveillance modelling for horticulture biosecurity threats

Plant Biosecurity Cooperative Research Centre

This document summarizes research aimed at improving biosecurity decision making for plant pathogens through surveillance modeling. The researchers are developing models and protocols to optimize quarantine zone setting, eradication strategies, and incursion responses. Models of Panama Tropical Race 4 spread and Queensland fruit fly population genetics inform decision processes. The research will deliver publications, conferences, software, and training to benefit state governments, surveillance providers, and horticultural industries through smarter pest detection and control.

Genetic molecular markers to accelerate genetic gains in crops

ICRISAT

Accelerating and delivering genetic gains in smallholder farmers’ fields is high on international agricultural research agenda, especially in Asia and sub-Saharan Africa. This will help in improving crop productivity, better yield and higher income for farmers and most importantly achieving food and nutrition security in developing countries. Conventional plant breeding approaches have contributed immensely to this; however, they have limitations in terms of delivering improved varieties with desired traits in a time-bound manner. Genomics tools and technologies have changed methods of plant breeding in a positive direction.

Dr. Patrick McDermott - One Health Antibiotic Stewardship State of Science - ...

John Blue

This document summarizes the 20-year history and strategic plans of the National Antimicrobial Resistance Monitoring System (NARMS). NARMS monitors antimicrobial resistance in foodborne bacteria to inform human and veterinary medicine. The strategic plan includes improving sampling representativeness, data analysis and reporting, collaborative research, and international partnerships. Advances in whole genome sequencing and metagenomics now allow comprehensive resistance gene detection and correlations between genotypes and phenotypes. Moving forward, NARMS aims to expand surveillance within a One Health framework.

Plant pest impacts: a common set of metrics

Plant Biosecurity Cooperative Research Centre

Detection and surveillance of phylloxera using qPCR

Plant Biosecurity Cooperative Research Centre

This document discusses the development of a protocol for detecting the grape pest phylloxera using quantitative PCR (qPCR) in soil samples. The objectives are to create a sampling and detection method that is accurate, sensitive, cost-effective and can be applied to other pests. It aims to obtain endorsement to incorporate the qPCR method into the national phylloxera management standard. The research aims to benefit the wine industry through improved surveillance and early detection of phylloxera, as well as regulators and researchers.

Advanced Report Customization via VSClinical

Golden Helix

This document provides a summary of a presentation about advanced customization capabilities for clinical reports using VSClinical software: - VSClinical allows customization of clinical reports through custom HTML, XML, JSON templates and scripts to enhance Word reports and integrate with REST APIs. - Templates are provided for germline and somatic variant analysis that include ACMG/AMP guidelines and can be further customized. - Reports can include additional data such as gene impact analysis, drug/trial information, and machine-readable outputs like JSON can be generated. - A product demo was given to showcase report customization features.

Annotation capabilities

Golden Helix

VarSeq provides powerful annotation capabilities for variant analysis including gene tracks, assemblies, variant functions, frequency tracks, functional predictions, and transcript annotations. It integrates information from over 20 public databases and sources and updates annotations monthly to provide the most current clinically relevant information for researchers. By centralizing variant annotations from disparate sources, VarSeq saves customers significant time and resources compared to manual curation of this data.

An Exploration of Clinical Workflows in VarSeq

Golden Helix

In this webcast, we feature several example workflows and helpful features in the VarSeq that can be used in the clinic. We discuss options for conducting a comprehensive gene panel analysis for cancer or hereditary diseases. Then we introduce an example of a single exome workflow that goes from an unfiltered VCF created by a secondary analysis pipeline to a report containing information about interesting variants. Finally, we walk through an example of a trio analysis showcasing a variety of different filter options as well as inheritance patterns. All these workflows will result in a customizable clinical report.

Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...

Golden Helix

This document summarizes a presentation given by Gabe Rudy, VP of Product & Engineering at Golden Helix, on updated strategies and expanded capabilities for exome analysis with VS-CNV and VSClinical. The presentation demonstrates new features for enhanced variant analysis, including analyzing splice site, non-coding RNA, and mitochondrial variants. It also reviews improvements to Golden Helix's exome CNV calling in VarSeq, including a new low-quality target filter strategy that reduces the number of CNVs called while maintaining sensitivity and precision. Additional capabilities discussed include generating synchronized clinical reports and incorporating virtual gene panels.

Introducing VSClinical AMP Guidelines: A Comprehensive Workflow for NGS Testi...

Golden Helix

Golden Helix is introducing new guidelines for next-generation sequencing (NGS) testing of cancer samples using their VSClinical software. The AMP guidelines provide a comprehensive workflow for variant filtering, annotation, classification evidence levels, and integrated clinical reporting of somatic and germline variants. The software utilizes various data sources to aid in cancer interpretation and allows users to save and reuse interpretations. An upcoming webinar will demonstrate how to score somatic variants for oncogenicity using VSClinical.

Overview of-device-regulation-fda-san-diego-ca

GlobalCompliancePanel

Vaxin Notice of Allowance Release.final

Bill Enright

Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, has been granted Notices of Allowance from the USPTO for two new patents protecting elements of its hepatitis B and influenza vaccine candidates. The patents cover an aqueous formulation for Vaxin's HepTcell hepatitis B immunotherapy product and the intranasal administration of its NasoVax influenza vaccine to induce immune responses. With these additions, Vaxin now has 37 patents in 13 countries protecting its products. The company is on track to begin three phase 1 clinical trials within the next 9 months.

AMP-Based Variant Classification with VSClinical

Golden Helix

The document discusses Golden Helix's VSClinical software and its capabilities for analyzing biomarkers and variants according to AMP and ACMG guidelines. VSClinical provides a four-phased workflow to 1) filter variants, 2) assess evidence, 3) develop classifications, and 4) include interpretations in clinical reports. It leverages Golden Helix's CancerKB knowledgebase to accelerate variant interpretation and standardized reporting. The document demonstrates VSClinical's analysis and reporting of variants from a myeloid gene panel according to AMP guidelines.

Non-Resistant Antimicrobial Therapy: Treating Superbugs That Cause Nosocomial...

kphodel

This document discusses a new treatment for hospital-acquired pneumonia (HAP) using a combination of SynAmp, a non-antibiotic compound that enhances antibiotic potency, and an antibiotic. HAP is a major problem with high mortality and increasing antibiotic resistance. The combination therapy is a first-line treatment for HAP that is dosed once daily and shows no resistance after 30 days. It has intellectual property protection and competitive advantages over current treatments. With expedited regulatory pathways, the company aims to launch the primary HAP indication with $200 million in annual sales and expand to other infections. Funding is sought to further develop the pre-clinical candidate.

Avalanche Biotech

Healthegy

1) Avalanche Biotechnologies is developing gene therapy treatments for eye diseases using its Ocular BioFactoryTM platform. Its lead product AVA-101 has shown promising clinical results for wet age-related macular degeneration (AMD) with patients gaining or maintaining vision with few additional treatments needed over one year. 2) Avalanche has an integrated gene therapy discovery, development and manufacturing platform and a pipeline of other programs including a collaboration with Regeneron. It has an experienced management team in the areas of gene therapy and ophthalmology. 3) The company highlights its potential to develop one-time transformative treatments for major sight-threatening diseases in ophthalmology using its Ocular BioFactoryTM platform

Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody

kphodel

Nuts and Bolts of GMOs - Harold Trick

Mary-Katherine Kearney

This document provides an overview of genetically modified organisms (GMOs) presented at a conference for women farmers. It defines GMOs and the process of genetic engineering used to create them. The presentation discusses why GMOs are made, whether they are safe, and how they are regulated. It provides examples of commercialized GMO crops and their benefits, such as herbicide and insect resistance. Potential risks like environmental impacts and health issues are addressed, but major scientific organizations have found GMO risks to be no different than conventional crops. The process of developing and commercializing a GMO crop takes over 13 years and over $136 million.

David Glass Presentation at 2010 Algae Biomass Summit

David Glass

What's hot

Current risk assessment approaches for environmental and food & feed safety -...

OECD Environment

OECD Co-operative research programme - Gary Fitt

OECD Environment

Regulatory aspects associated to genome editing in Australia - situation for ...

OECD Environment

Molecular basis of response to (sub)lethal stresses in Tephritid fruit flies

Plant Biosecurity Cooperative Research Centre

Quarantine and surveillance modelling for horticulture biosecurity threats

Plant Biosecurity Cooperative Research Centre

Genetic molecular markers to accelerate genetic gains in crops

ICRISAT

Dr. Patrick McDermott - One Health Antibiotic Stewardship State of Science - ...

John Blue

Plant pest impacts: a common set of metrics

Plant Biosecurity Cooperative Research Centre

Detection and surveillance of phylloxera using qPCR

Plant Biosecurity Cooperative Research Centre

Advanced Report Customization via VSClinical

Golden Helix

Annotation capabilities

Golden Helix

An Exploration of Clinical Workflows in VarSeq

Golden Helix

Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...

Golden Helix

Introducing VSClinical AMP Guidelines: A Comprehensive Workflow for NGS Testi...

Golden Helix

Overview of-device-regulation-fda-san-diego-ca

GlobalCompliancePanel

Vaxin Notice of Allowance Release.final

Bill Enright

AMP-Based Variant Classification with VSClinical

Golden Helix

Non-Resistant Antimicrobial Therapy: Treating Superbugs That Cause Nosocomial...

kphodel

Avalanche Biotech

Healthegy

Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody

kphodel

What's hot (20)

Current risk assessment approaches for environmental and food & feed safety -...

OECD Co-operative research programme - Gary Fitt

Regulatory aspects associated to genome editing in Australia - situation for ...

Molecular basis of response to (sub)lethal stresses in Tephritid fruit flies

Quarantine and surveillance modelling for horticulture biosecurity threats

Genetic molecular markers to accelerate genetic gains in crops

Dr. Patrick McDermott - One Health Antibiotic Stewardship State of Science - ...

Plant pest impacts: a common set of metrics

Detection and surveillance of phylloxera using qPCR

Advanced Report Customization via VSClinical

Annotation capabilities

An Exploration of Clinical Workflows in VarSeq

Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...

Introducing VSClinical AMP Guidelines: A Comprehensive Workflow for NGS Testi...

Overview of-device-regulation-fda-san-diego-ca

Vaxin Notice of Allowance Release.final

AMP-Based Variant Classification with VSClinical

Non-Resistant Antimicrobial Therapy: Treating Superbugs That Cause Nosocomial...

Avalanche Biotech

Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody

Similar to 1 Jennifer Kuzma USDA Rule Panel, 6-5-2020

Nuts and Bolts of GMOs - Harold Trick

Mary-Katherine Kearney

David Glass Presentation at 2010 Algae Biomass Summit

David Glass

Terminology & Legal Issues Biotech Crops Redick

Thomas Redick

Foodborne Illness: Prevention and Response

National Restaurant Association

Genetic Modified Organism Regulation in India

MeehirMerai

The document discusses India's standards for the release and use of genetically modified organisms (GMOs). It provides definitions of GMOs and explains how they are created by inserting foreign genes into organisms' DNA. It then discusses the main benefits of genetically modifying agricultural plants and animals. The document goes on to summarize India's policies and regulatory framework for ensuring biosafety of GMOs, including guidelines, committees, and containment facilities required for research. It also notes the countries that use GMO technology the most and some concerns about their use.

National and International Regulatory Framework for GM Crops_2015

Asian Food Regulation Information Service

This document discusses regulatory frameworks for genetically modified crops at the national and international level. It provides an overview of: - International efforts in food safety and principles of GM food safety assessment. - How different countries/regions like the US, Canada, EU, Argentina, India, etc. have different agencies that regulate GM crop food safety and environmental release. The definitions of GMOs also vary between countries' laws. - India's regulatory framework is established under the Environment Protection Act 1986. Key agencies involved include GEAC, RCGM and SBCC. Guidelines development involves expert consultation and consideration of research. - The process for developing a GM crop in India involves extensive molecular, compositional and safety assessment

What makes a city a hub of entrepreneurship? Successes and reinvestment.

James McCarter

genetic-modification-and-gene-editing-ppt-1416wfcf.pptx

HanySaid33

Genetic modification and gene editing techniques allow scientists to alter genes in crops and livestock in order to produce desirable traits more rapidly than traditional breeding methods. While genetically modified foods may have benefits like increased nutrient levels or resistance to pests and drought, there are also concerns about potential health risks and environmental impacts. Gene editing provides a targeted way to modify genes and could help address some concerns about genetic modification, but there are still legal and social issues surrounding new food technologies.

David Glass BIO World Congress Synthetic Biology Regulation july 2015

David Glass

Legal Implications and Public Concerns in Genetic Mortification of foods, rat...

Daffodil International University

Genetically engineered foods

SDAAH

International and National guidelines regarding use of genetically modified ...

berciyalgolda1

This document provides an overview of international and national guidelines regarding the use of genetically modified organisms (GMOs) in the environment, food, and pharmaceuticals. It defines GMOs and the genetic engineering techniques used to create them. It discusses where GMOs are currently used and the safety issues considered in their risk assessments, including potential toxicity, allergenicity, and nutritional impacts. The document also outlines India's regulatory framework for GMOs, including the various committees and guidelines established under the Rules of 1989 to ensure their safe research, development, and environmental release.

transgenic crops and their regulatory system

Guru P N

This document summarizes the steps involved in developing transgenic crops and the regulatory approval system for biotech crops in India. It discusses how transgenic crops are created by introducing transgenes using techniques like Agrobacterium transformation. It also outlines the Indian regulatory system overseen by organizations like GEAC, RCGM and IBSC that aim to ensure the safety of GM crops. The system involves approvals for research, field trials and environmental release of transgenic crops. However, limitations of the current system are that it lacks adequate risk assessment standards and procedures and does not fully incorporate international biosafety protocols.

Raising Awareness and Discovering the Dirt 12345 .docx

robert345678

Raising Awareness and Discovering the Dirt 12345 Canyon Dr., Northridge, CA 91344 (818) 555-9089 (818) 555-9222 Radd.com RADD What role can the FDA play in regulating GMO products? This brief is intended for the United States Food and Drug Administration (FDA) and is presented on behalf of Raising Awareness and Discovering the Dirt (RADD). RADD is a non-profit organization committed to promoting the wellness of the environment. Since the earlier 1990s, commercialization of Genetic Modified Organisms (GMOs) has spread throughout the U.S. The FDA has promoted a program of self-regulation among the biotech crop and food developers (www.fda.gov). Many of the biotech food and crop developers’ primary interest is the development of high-yielding products. For example, Monsanto, a biotech food and crop developer’s director of corporate communications, Philip Angell was quoted saying; “Monsanto should not have to vouchsafe the safety of biotech food. Our interest is in selling as much of it as possible. Assuring its safety is the FDA’s job,” (Antoniou, Robinson, & Fagan, 2012, p. 23). Finally, research and Monsanto’s own feeding trials revealed health-effects and suggest that more suitable options are needed to maintain the safety of consumers and the environment. Therefore, RADD is committed to working with the FDA in creating programs that will ensure the safety of environment and the use of GMOs. Statement of Issue: In order to promote awareness and ultimately protect the health of consumers, the FDA has the ability to regulate GMOs by establishing new guidelines. There is a growing body of evidence that connects GMOs with health problems, environmental damage, and violation of rights of farmers and consumers. Studies show a correlation between GMOs and health problems such as production of new allergens increased toxicity, decreased nutrition, and antibiotic resistance (Bernstein et al., 2003). Additionally, since the emergence of GMO crops, there has been an increase in the amount of agriculture changes. Such changes include the development of “massive weeds” and “super bugs,” both requiring an increased dosage of toxins to rid of these unwanted, overgrown organisms. In return, consumers are now ingesting these increased dosages of toxins. Background: Ultimately, the only beneficiaries of products containing GMOs are its producers, such as, Monsanto, rather than consumers. Monsanto makes an abundant amount of profit on their GMO products as they have scientifically modified crops, allowing them to have faster results. The “proposed” purpose of GMOs was to increase yield and enhance nutritional value, while also lowering the use of pesticides. (www.nongmoproject.org, 2013). Indeed, the use of GMOs increase yield, but studies show that GMO products hold no nutritional value and rather, by decreasing the use of pesticides, there has been an increase .

GENE-EDITING-ETHICAL-AND-SOCIETAL-IMPLICATIONS - Copy.pptx

JOEYJIMENEZ7

Gene editing is a new technology that allows precise modifications to DNA sequences. It holds promise for treating diseases, enhancing crops, and modifying human embryos, but also raises complex ethical issues that require careful consideration. This presentation will explore both the technical aspects and far-reaching implications of gene editing from medical, agricultural, and societal perspectives, addressing concerns around safety, germline editing, and ensuring equitable access to its benefits.

The Documented Health Risks of Genetically Engineered Foods (Long Version)

Jack Olmsted

Content of the Presentation Regulatory Failure: It is useful to explain how such dangerous products could have made it to the market with government approval. Several slides include quotes from formerly secret FDA documents that show how government policy was at odds with more cautious scientific opinion at the agency. Health Risks of GMOs: This section highlights many of the adverse findings revealed through laboratory experiments and reported by farmers, doctors, and investigators. It also introduces some theoretical risks based on the current state of the science. The Consumer Tipping Point: The final section includes a discussion of a strategy to achieve the tipping point of consumer rejection of GMOs in the US, which is the basis for our Campaign for Healthier Eating in America. The key elements needed are consumer education on GMO health risks combined with clear non-GMO choices. The Institute for Responsible Technology http://www.responsibletechnology.org/resources/powerpoint-presentation-on-gmos

Science of Genetic Engineering as it relates to the California Initiative to ...

Belinda Martineau

FDA Corruption

Allan Marsh

intelectual property rights on transgenics

Anilkumar C

This document discusses transgenic crops, including their promises such as increased food production and quality as well as reduced pesticide usage. It outlines the process of making transgenic plants and provides an overview of GM crop status globally and in India. The document also discusses the handling, testing, and regulatory issues around transgenic crops, including the various competent authorities and categories of genetic engineering experiments in India. It notes the infrastructure needed to work with transgenic crops, including laboratory, greenhouse, and field facilities, and the roles of public and private sectors in agricultural biotechnology research.

Regulation and intellectual property of agricultural biotechnologies: Perspe...

ExternalEvents

Similar to 1 Jennifer Kuzma USDA Rule Panel, 6-5-2020 (20)

Nuts and Bolts of GMOs - Harold Trick

David Glass Presentation at 2010 Algae Biomass Summit

Terminology & Legal Issues Biotech Crops Redick

Foodborne Illness: Prevention and Response

Genetic Modified Organism Regulation in India

National and International Regulatory Framework for GM Crops_2015

What makes a city a hub of entrepreneurship? Successes and reinvestment.

genetic-modification-and-gene-editing-ppt-1416wfcf.pptx

David Glass BIO World Congress Synthetic Biology Regulation july 2015

Legal Implications and Public Concerns in Genetic Mortification of foods, rat...

Genetically engineered foods

International and National guidelines regarding use of genetically modified ...

transgenic crops and their regulatory system

Raising Awareness and Discovering the Dirt 12345 .docx

GENE-EDITING-ETHICAL-AND-SOCIETAL-IMPLICATIONS - Copy.pptx

The Documented Health Risks of Genetically Engineered Foods (Long Version)

Science of Genetic Engineering as it relates to the California Initiative to ...

FDA Corruption

intelectual property rights on transgenics

Regulation and intellectual property of agricultural biotechnologies: Perspe...

More from Genetic Engineering & Society Center

Kuzma OSTP and biotechnology oversight policy

1 Jennifer Kuzma USDA Rule Panel, 6-5-2020

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to 1 Jennifer Kuzma USDA Rule Panel, 6-5-2020

Similar to 1 Jennifer Kuzma USDA Rule Panel, 6-5-2020 (20)

More from Genetic Engineering & Society Center

More from Genetic Engineering & Society Center (17)

Recently uploaded

Recently uploaded (20)

1 Jennifer Kuzma USDA Rule Panel, 6-5-2020